<DOC>
	<DOCNO>NCT01965106</DOCNO>
	<brief_summary>This study assess side effect may occur QPI-1007 injected eye subject acute primary angle-closure glaucoma , well long take body clear drug . This study also test whether QPI-1007 , inject eye , help prevent structural damage nerve tissue eye loss visual function subject acute primary angle-closure glaucoma .</brief_summary>
	<brief_title>Phase IIA Double-Masked Randomized Sham-Controlled Trial QPI-1007 Delivered Single Intravitreal Injection Subjects With Acute Primary Angle-Closure Glaucoma ( APACG )</brief_title>
	<detailed_description>This Phase IIa double-masked , single dose , randomize , sham-controlled study evaluate safety tolerability , pharmacokinetics QPI-1007 versus Control ( sham procedure ) subject acute attack primary angle-closure glaucoma . Subjects randomize ratio 1:1 one two study arm : 1.5 QPI-1007 arm Control arm ( sham procedure ) . The study enroll approximately 30 subject arm . Randomization stratify time symptom onset study drug administration sham procedure ( â‰¤72 hour &gt; 72 hour ) .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Angle-Closure</mesh_term>
	<criteria>Males female age least 40 year old . Onset symptom acute attack primary angleclosure study eye within 120 hour prior plan study drug administration . Bestcorrected visual acuity ( BCVA ) 20/40 good study eye resolution acute attack . Received successful treatment acute attack angleclosure , undergone laser iridotomy intraocular pressure study eye &lt; 25mm Hg . Sufficiently clear ocular medium adequate pupil dilation allow optic nerve fovea visualize assess study eye . Female subject must : ( 1 ) post menopausal , ( 2 ) surgically sterile , ( 3 ) use effective mean contraception . Previously diagnose glaucoma either eye . The time plan study drug administration 120 hour onset symptom . History chronic angleclosure either eye . Secondary angleclosure/secondary angleclosure glaucoma study eye . Monocular subject . Prior incisional intraocular surgery . Inability perform reliable visual field test Day 0 study eye . History panretinal photocoagulation macular laser photocoagulation study eye . History active malignancy within last 5 year ( however , non facial , basal cell carcinoma allow ) . History myocardial infarction within last 6 month . Received drug know cause optic nerve retinal toxicity within 14 day prior dose . Women pregnant lactating . Participating concurrent interventional study last intervention occur within 30 day prior plan dose QPI1007 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Glaucoma , Angle-Closure</keyword>
	<keyword>Glaucoma , Closed-Angle</keyword>
	<keyword>Primary angle closure</keyword>
	<keyword>Acute angle closure</keyword>
	<keyword>Acute angle-closure glaucoma</keyword>
</DOC>